Prof. Reproductive & Neonatal Infectious Diseases, Department of Obstetrics and Gynaecology, University of Melbourne, Director Centre Women’s Infectious Diseases Research, Royal Women’s Hospital and Honorary Research Fellow, Infection & Immunity, Murdoch Children’s Research Institute.
Professor Garland is an internationally recognized clinical microbiologist and sexual health physician, with particular expertise in infectious diseases as they pertain to reproductive health and the neonate. With her team, Prof Garland, has been a leader in the role of patient self-collected genital sampling in the detection by molecular techniques such as PCR, of reproductive tract infections, particularly those sexually transmitted (STI), such as Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, herpes simplex virus and especially human papillomaviruses (HPV).
She has published extensively on clinical epidemiology of STIs in Australia, with a focus on HPV. Her group has defined HPV in cervical dysplasia, cervical cancer, plus the healthy population within Australia. She was chief investigator of the study defining the prevalence of HPV genotypes in urban, rural, indigenous and non-indigenous Australian women (WHINURS project) pre-HPV vaccination program in Australia. She was chief investigator clinical trials of prophylactic HPV vaccines in young women, plus one in mid-age women. She led an HPV vaccine effectiveness trial in Australia which has been informative globally, particularly with the WHINURS data as baseline to compare outcomes post vaccination. Her team is responsible for genoprevalence surveillance nationally as a marker of vaccine outcome.
She is a regular Advisor to the WHO, largely in the area of STI diagnosis, prophylactic HPV vaccines, international standards for HPV DNA assays and Working group on HPV to SAGE. She has published over 750 peer-reviewed articles.
Whilst key research areas of focus include cervical cancer, sexual health and mother-to-baby infections, it has an emphasis on providing evidence for changes that may translate into clinical practice, affecting patient health.
She is Past and Inaugural President and ongoing Board member of AOGIN (Asia Oceania research organization on Genital Infections and Neoplasia) and Co-Chair of a new group focusing on the Asia-Pacific region (APAC HPV Coalition).